Predictors and Nomogram prediction model of in-stent restenosis within 2 years after drug-eluting stents implantation
Author:
Affiliation:

1.Hengyang Medical School, University of South China, Hengyang, Hunan 421001, China;2.Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen, Guangdong 518000, China;3.Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangdong 518021, China)

Clc Number:

R5

  • Article
  • | |
  • Metrics
  • |
  • Reference [25]
  • |
  • Related
  • | | |
  • Comments
    Abstract:

    Aim To investigate the risk factors of in-stent restenosis (ISR) within 2 years after the implantation of drug-eluting stent (DES) in patients with coronary heart disease and type 2 diabetes, and construct a Nomogram prediction model. Methods Clinical data of patients with coronary heart disease and type 2 diabetes who received DES at the Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen from January 2010 to February 2020 were retrospectively analyzed. The PASS estimation model generates cohort sample size, which was divided into ISR group (DES-ISR) and non-ISR (non-DES-ISR) group based on the results of coronary angiography. The single factor and conditional multivariate Logistic regression analysis were performed on the parameters with statistical significance between the two groups, and the Nomogram prediction model was constructed and its reliability was verified in the validation cohort. Results A total of 1 741 cases were included in model generated cohort, 233 cases (13.4%) were diagnosed with ISR within 2 years after implantation of DES. Conditional multivariate Logistic regression analysis showed that the predictor of DES-ISR was estimated glomerular filtration rate (eGFR)<60 mL/(min·1.73 m2) (OR=2.7,5%CI:1.41~5.47, P=0.003), dyslipidemia (OR=1.0,5%CI:1.30~2.78, P=0.001), fasting blood glucose (FPG) ≥6.5 mmol/L (OR=5.0,5%CI:3.05~9.92, P<0.001), multivessel coronary artery disease (OR=7.6,5%CI:3.27~16.11, P<0.001), diffuse coronary artery disease (OR=1.0,5%CI:1.13~2.88, P=0.014), primary PCI operation time ≥60 min (OR=2.2,5%CI:1.13~6.05, P=0.024) and emergency PCI (OR=2.0,5%CI:1.48~3.28, P<0.001). The model validation cohort contained 102 cases, the risk of DES-ISR increased with the increase of the Nomogram scores. The area under the receiver operating characteristic (ROC) curve of the Nomogram model was 0.791 (95%CI:0.753~0.829, P=0.019). Conclusions The anatomical characteristics of coronary artery and PCI procedures are important predictors of DES-ISR. Nomogram can effectively identify high-risk groups of DES-ISR and provide effective decision-making information for follow-up and intervention of high-risk groups.

    Reference
    [1] 中国心血管健康与疾病报告2020概要 .中国循环杂志, 1,6(6):521-545.
    [2] STONE G W, KAPPETEIN A P, SABIK J F, et al.Five-year outcomes after PCI or CABG for left main coronary disease.N Engl J Med, 0,2(11):1078.
    [3] HEAD S J, DAVIERWALA P M, SERRUYS P W, et al.Coronary artery bypass grafting vs.percutaneous coronary intervention for patients with three-vessel disease:final five-year follow-up of the SYNTAX trial.Eur Heart J, 4,5(40):2821-2830.
    [4] KAPPETEIN A P, HEAD S J, MORICE M C, et al.Treatment of complex coronary artery disease in patients with diabetes:5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial.Eur J Cardiothorac Surg, 3,3(5):1006-1013.
    [5] JOHANNSEN L, SOLDAT J, KRUEGER A, et al.Impact of diabetes mellitus on outcomes after high-risk interventional coronary procedures.J Clin Med, 0,9(11):3414.
    [6] WANG F, LI C, DING F H, et al.Increased serum TREM-1 level is associated with in-stent restenosis, and activation of TREM-1 promotes inflammation, proliferation and migration in vascular smooth muscle cells.Atherosclerosis, 7,7:10-18.
    [7] XIU W J, YANG H T, ZHENG Y Y, et al.Drug-eluting balloons versus second-generation drug-eluting stents for treating In-Stent restenosis in coronary heart disease after PCI:a Meta-analysis.Cardiol Res Pract, 8,8:7658145.
    [8] LEE M S, BANKA G.In-stent restenosis.Interv Cardiol Clin, 6,5(2):211-220.
    [9] GIACOPPO D, ALFONSO F, XU B, et al.Paclitaxel-coated balloon angioplasty vs.drug-eluting stenting for the treatment of coronary in-stent restenosis:a comprehensive, collaborative, individual patient data Meta-analysis of 10 randomized clinical trials (Daedalus study).Eur Heart J, 0,1(38):3715-3728.
    [10] STOLKER J M, KENNEDY K F, LINDSEY J B, et al.Predicting restenosis of drug-eluting stents placed in real-world clinical practice:derivation and validation of a risk model from the EVENT registry.Circ Cardiovasc Interv, 0,3(4):327-334.
    [11] 陈劲松, 陈韵岱, 田峰, 等.冠心病合并糖尿病患者药物洗脱支架置入后2年支架内再狭窄的预测因素.中华心血管病杂志, 4,2(1):14-18.
    [12] STANKOVIC G, MANGINAS A, VOUDRIS V, et al.Prediction of restenosis after coronary angioplasty by use of a new index:TIMI frame count/minimal luminal diameter ratio.Circulation, 0,1(9):962-968.
    [13] 韩雅玲.中国经皮冠状动脉介入治疗指南(2016).中华心血管病杂志, 6,4(5):382-400.
    [14] 中华医学会糖尿病学分会, 国家基层糖尿病防治管理办公室.国家基层糖尿病防治管理指南(2018) .中华内科杂志, 8,7(12):885-893.
    [15] GARCIA-GARCIA H M, MCFADDEN E P, FARB A, et al.Standardized end point definitions for coronary intervention trials:the academic research consortium-2 consensus document.Circulation, 8,7(24):2635-2650.
    [16] SHLOFMITZ E, IANTORNO M, WAKSMAN R.Restenosis of drug-eluting stents:a new classification system based on disease mechanism to guide treatment and state-of-the-art review.Circ Cardiovasc Interv, 9,2(8):e007023.
    [17] CUTLIP D, CHHABRA A G, BAIM D S, et al.Beyond restenosis:five-year clinical outcomes from second-generation coronary stent trials.Circulation, 4,0(10):1226-1230.
    [18] 张海福, 张媛媛, 张琴霞, 等.生物可吸收聚合物涂层药物洗脱支架与耐用聚合物涂层药物洗脱支架在冠心病合并糖尿病患者中应用的比较:临床试验Meta分析.中国动脉硬化杂志, 1,9(1):74-81.
    [19] NAKAMURA D, DOHI T, ISHIHARA T, et al.Predictors and outcomes of neoatherosclerosis in patients with in-stent restenosis.EuroIntervention, 1,7(6):489-496.
    [20] XIAO S, ZHANG L, WU Q, et al.Development and validation of a risk nomogram model for predicting revascularization after percutaneous coronary intervention in patients with acute coronary syndrome.Clin Interv Aging, 1,6:1541-1553.
    [21] FARKOUH M E, DOMANSKI M, DANGAS G D, et al.Long-term survival following multivessel revascularization in patients with diabetes:the FREEDOM follow-on study.J Am Coll Cardiol, 9,3(6):629-638.
    [22] YONETSU T, KATO K, KIM S J, et al.Predictors for neoatherosclerosis:a retrospective observational study from the optical coherence tomography registry.Circ Cardiovasc Imaging, 2,5(5):660-666.
    [23] OSRIO G V, BLAYA P, LASEVITCH R, et al.Impact of chronic kidney disease on the efficacy of drug-eluting stents:long-term follow-up study.Arq Bras Cardiol, 1,6(5):346-351.
    [24] VLAAR P J, DE SMET B J, VAN DEN HEUVEL A F, et al.Operator dependence of outcome after primary percutaneous coronary intervention.EuroIntervention, 1,6(6):760-767.
    [25] KAMENIK M, WIDIMSKY P.Stent thrombosis in acute coronary syndromes:patient-related factors and operator-related factors.Anatol J Cardiol, 0,4(4):274-279.
    Related
    Cited by
Get Citation

YI Ming, XU Shuai, LIU Qiang, KE Xiao. Predictors and Nomogram prediction model of in-stent restenosis within 2 years after drug-eluting stents implantation[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2022,30(1):59-64, 82.

Copy
Share
Article Metrics
  • Abstract:584
  • PDF: 717
  • HTML: 0
  • Cited by: 0
History
  • Received:February 21,2021
  • Revised:November 03,2021
  • Online: January 07,2022
Article QR Code